Acute stroke imaging research roadmap by Wintermark, M. et al.
 
 
 
 
 
 
 
Wintermark, M., Albers, G.W., Alexandrov, A.V., Alger, J.R., Bammer, 
R., Baron, J.-C., Davis, S., Demaerschalk, B.M., Derdeyn, C.P., Donnan, 
G.A., Eastwood, J.D., Fiebach, J.B., Fisher, M., Furie, K.L., Goldmakher, 
G.V., Hacke, W., Kidwell, C.S., Kloska, S.P., Kohrmann, M., Koroshetz, 
W., Lee, T.Y. and Lees, K.R.  (2008) Acute stroke imaging research 
roadmap. Stroke, 39 (5). pp. 1621-1628. ISSN 0039-2499 
 
http://eprints.gla.ac.uk/17937/ 
 
Deposited on: 19 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Wardlaw, Ona Wu and Steven Warach
Provenzale, Peter Schellinger, Robert Silbergleit, Alma Gregory Sorensen, Joanna
Michael H. Lev, David S. Liebeskind, Leif Ostergaard, William J. Powers, James 
P. Kloska, Martin Köhrmann, Walter Koroshetz, Ting-Yim Lee, Kennedy R. Lees,
Karen L. Furie, Gregory V. Goldmakher, Werner Hacke, Chelsea S. Kidwell, Stephan 
Derdeyn, Geoffrey A. Donnan, James D. Eastwood, Jochen B. Fiebach, Marc Fisher,
Bammer, Jean-Claude Baron, Stephen Davis, Bart M. Demaerschalk, Colin P. 
Max Wintermark, Gregory W. Albers, Andrei V. Alexandrov, Jeffry R. Alger, Roland
Acute Stroke Imaging Research Roadmap
ISSN: 1524-4628 
Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/STROKEAHA.107.512319
2008, 39:1621-1628: originally published online April 10, 2008Stroke 
 http://stroke.ahajournals.org/content/39/5/1621
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
Acute Stroke Imaging Research Roadmap
Max Wintermark, MD; Gregory W. Albers, MD; Andrei V. Alexandrov, MD; Jeffry R. Alger, PhD;
Roland Bammer, PhD; Jean-Claude Baron, MD; Stephen Davis, MD, FRCP, Edin FRACP;
Bart M. Demaerschalk, MD, MSc, FRCP(C); Colin P. Derdeyn, MD;
Geoffrey A. Donnan, MD, FRACP; James D. Eastwood, MD; Jochen B. Fiebach, MD;
Marc Fisher, MD; Karen L. Furie, MD, MPH; Gregory V. Goldmakher, MD, PhD;
Werner Hacke, MD, PhD; Chelsea S. Kidwell, MD; Stephan P. Kloska, MD; Martin Ko¨hrmann, MD;
Walter Koroshetz, MD; Ting-Yim Lee, PhD; Kennedy R. Lees, MD; Michael H. Lev, MD;
David S. Liebeskind, MD; Leif Ostergaard, MD, MSc, PhD, DMSc; William J. Powers, MD;
James Provenzale, MD; Peter Schellinger, MD, PhD; Robert Silbergleit, MD;
Alma Gregory Sorensen, MD; Joanna Wardlaw, MD; Ona Wu, PhD; Steven Warach, MD, PhD
Abstract—The recent “Advanced Neuroimaging for Acute Stroke Treatment” meeting on September 7 and 8, 2007 in
Washington DC, brought together stroke neurologists, neuroradiologists, emergency physicians, neuroimaging research
scientists, members of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), industry representatives, and members of the US Food and Drug
Administration (FDA) to discuss the role of advanced neuroimaging in acute stroke treatment. The goals of the meeting
were to assess state-of-the-art practice in terms of acute stroke imaging research and to propose specific recommen-
dations regarding: (1) the standardization of perfusion and penumbral imaging techniques, (2) the validation of the
accuracy and clinical utility of imaging markers of the ischemic penumbra, (3) the validation of imaging biomarkers
relevant to clinical outcomes, and (4) the creation of a central repository to achieve these goals. The present article
summarizes these recommendations and examines practical steps to achieve them. (Stroke. 2008;39:1621-1628.)
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On September 7 and 8, 2007, the National Institute ofHealth, in conjunction with the American Society of
Neuroradiology and the Neuroradiology Education & Re-
search Foundation, sponsored a research symposium entitled
Advanced NeuroImaging for Acute Stroke Treatment. The
first day of the symposium was devoted to presentations that
provided an overview of technical and clinical aspects of
acute stroke imaging, including perfusion imaging. These
presentations focused on topics that remain, to some extent,
controversial and for which a higher degree of consensus is
needed for research to proceed. For instance, the appropriate
way to image the ischemic penumbra, ie, the region of
hypoperfused—but not yet infracted—tissue at risk to pro-
ceed to infarction, and its exact role in triaging patients for
therapy were debated. A number of issues with regard to
study design and patient selection for clinical trials were also
reviewed in detail. The second day consisted of 3 concurrent
workshops, with 1 on each of the following major themes: (1)
standardization of perfusion and penumbra imaging terminol-
ogy and methodology, (2) trial design and patient selection
for acute reperfusion therapy, and (3) development of multi-
center collaborations and repositories to demonstrate that
advanced stroke imaging improves acute stroke patients’
outcomes. This report provides the salient points of the
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meeting, outlines the unresolved issues, and proposes the
creation of a consortium that would greatly advance our
efforts to overcome these issues. Specifically, this report
provides recommendations for stroke imaging research in
terms timing of imaging studies for acute stroke patients,
perfusion imaging protocols, and development of a central
repository for images that will facilitate answering of major
unresolved questions. There are important aspects of acute
stroke imaging that were not addressed during the meeting,
including the impact of advanced imaging findings on the
management of acute stroke patients beyond acute penumbral
salvage. These include identification of stroke subtype and
mechanism (small vessel versus large vessel disease, athero-
ma versus dissection), large vessel patency status, and lesion
volume, all of which have implications for acute and subacute
management decisions. The specific issues pertinent to tran-
sient ischemic attacks and their imaging were not discussed
either.
Recommended Timing for Research Imaging
Studies in Acute Stroke Patients
As a research model for evaluating the efficacy of reperfusion
therapies or other interventions, acute stroke patients enrolled
in clinical trials should ideally undergo imaging at 4 time
points. The respective contraindications to CT and MRI, and
to iodinated and gadolinium contrast material, should of
course be taken into consideration when selecting the imag-
ing modality and implementing the recommended time points
described below. The rationale for this imaging protocol is
detection of (1) the initial parenchymal and vascular state, (2)
the biological effect of the intervention, (3) the occurrence of
early hemorrhagic transformation, and (4) the final tissue
outcome.
1. At baseline, acute stroke patients should undergo either
a “baseline” MRI or CT study.
● Baseline MRI sequences should include: scout image,
diffusion-weighted imaging (DW; Table 1), 3D time-
of-flight MR-angiogram (MRA) of the intracranial
arteries, gradient-recalled echo (GRE) imaging,
perfusion-weighted imaging (PWI; Table 1), and
T2-fluid attenuated inversion recovery (FLAIR).
FLAIR images can be obtained before or after gado-
linium administration. Delayed postgadolinium
FLAIR images allow assessment for the presence of
the Hyperintense Acute Reperfusion Marker
Table 1. Recommended Acquisition Protocols for Perfusion-Weighted (PWI) and Diffusion-Weighted (DWI) MR Imaging
PWI DWI
Sequence Single-shot gradient-echo echoplanar imaging Single-shot diffusion-weighted spin-echo
echoplanar imaging
Image acquisition parameters TR1500 ms*
TE35 to 45 ms @ 1.5T
TE25 to 30 ms @ 3T
flip angle 60 to 90° @ 1.5T, 60° @ 3.0T
TR4000 ms but can be as high as needed to fit
all slices
TE minimum (partial Fourier)
b0 and 1000 sec/mm2
(at least 3 orthogonal directions)
eddy current correction
(dual-spin echo or postprocessing)
Parallel imaging and coil selected at the discretion of the site
Image acquisition duration 90 to 120 seconds
image acquisition started 10 seconds before initiation
of injection to achieve at least 10 to 12 baseline
images and also record slow uptake in stroke regions
90 to 260 seconds
Coverage and slice thickness Whole brain coverage using 12 slices
slice thickness 5 mm
gap 0 to 1 mm*
matrix size 128128*
phase-encoding along A/P direction
field of view 24 cm
Whole brain coverage using 12 slices
slice thickness 5 mm
gap 0 to 1 mm
matrix size 128128
phase-encoding along A/P direction
field of view 24 cm
Slice orientation Parallel to hard palate Parallel to hard palate
(ideally perpendicular to the scanner bore)
Contrast material Standard gadolinium-based contrast material   
Contrast volume Single dose (for half-molar agent, 20 mL for 100 kg
person) followed by 20 to 40 mL saline flush
  
Injection rate 4 to 6 mL per second (power injector required)
same injection rate for contrast and saline
  
IV access 18 to 20 gauge IV line
right antecubital vein preferred
  
Miscellaneous PWI can be performed before or after MR-angiography   
MRI scanner: 1.5T or 3T (MRI scanners with 512 image limit per series should be excluded).
*Interslice gap can be increased and matrix size can be decreased to achieve whole-brain coverage (TR can also be optimized to afford entire brain coverage but
should be 1500 to 2000 ms).
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(HARM) sign, possibly an indicator of early blood-
brain barrier disruption. Time-of-flight or gado-
linium-enhanced MRA to evaluate the cervical ca-
rotid and vertebral arteries should be obtained, either
at baseline (if it does not delay treatment) or at any
subsequent time point. Performing axial T1 fat-
suppressed images of the neck is left to each site’s
discretion.
● The baseline CT study should include: noncontrast
CT, perfusion CT (PCT; Table 2), CT-angiography
(CTA), and contrast-enhanced CT (PCT can be per-
formed before or after CTA). CTA must include the
intracranial and cervical arteries.
2. Typically 1 to 6 hours after treatment, patients enrolled
in research protocols should undergo either an MRI or a
CT study to assess for recanalization and reperfusion.
Indeed, arterial occlusion is the first event in the chain
of causality that leads to the stroke syndrome, perfusion
and diffusion imaging abnormalities, and ultimately
infarction. For treatments aiming at the recanalization
of the occluded artery, an appropriate assessment re-
quires baseline and posttreatment assessment of arterial
patency. The timing of the “reperfusion” scan should
reflect a sufficient duration of the investigational ther-
apy to demonstrate any effects. Ideally, the same
modality (and MR field strength/CT parameters) should
be used for the baseline and this “reperfusion” scan.
● The reperfusion/recanalization MRI study should in-
clude: scout image (no pregadolinium T1 required),
DWI (Table 1), 3D time-of-flight MRA of the intra-
cranial arteries, GRE, PWI (Table 1), and T2-FLAIR
(FLAIR images can be obtained before or after
gadolinium administration).
● The reperfusion/recanalization CT study should in-
clude: noncontrast CT, PCT (Table 2), and CTA,
which can be limited to the intracranial arteries if the
cervical arteries have been assessed at baseline
(again, PCT can be performed before or after CTA).
If the patient has (1) undergone endovascular or intra-arterial
(IA) therapy, or if the patient is (2) placed under continuous
transcranial Doppler monitoring, and the recanalization (or
persistent occlusion) status is known, then an MRA or CTA
is not required, but may be obtained to assess for possible
early reocclusion. PWI or PCT should be obtained in all cases
to assess tissue reperfusion (or lack thereof, particularly
considering the possibility of distal embolization after intraar-
terial therapy).
For treatments other than reperfusion therapies, such as
hyperoxia, induced hypertension, or collateral flow augmen-
tation, an “on-treatment” scan should be considered instead of
the “posttreatment”, “reperfusion” scan described above.
3. The third scan—either a noncontrast CT or GRE MRI
of the brain—is a “safety scan” to assess the safety of
investigational therapies, particularly with respect to the
presence and degree of any hemorrhagic transforma-
tion. It may be obtained systematically or only in case
of clinical worsening, typically between 24 and 72
hours after symptom onset.
4. A follow-up imaging study should be obtained to
determine the final infarct volume. The appropriate
timing for this follow-up scan is discussed below.
Recommended Perfusion Imaging
Acquisition Protocols
Both PWI and PCT will be important components of the
imaging studies collected from acute stroke patients and
contributed to the central repository described below. The
recommended imaging protocols for PWI and PCT are
summarized in Tables 1 and 2. They are based on a consensus
rather than solely evidence-based outcomes trials. The se-
Table 2. Recommended Acquisition Protocol for Perfusion-CT
(PCT)
Image acquisition rate 2 phases:
1st phase: 1 image per second,
duration30 to 45 seconds
2nd phase: 1 image per 2 to 3 seconds,
duration30 to 45 seconds
Total duration of the acquisition at least
70 to 90 seconds
Gantry rotation 1 second per gantry rotation
(up to every 3 seconds with “shuttle” or
“toggle table” mode)
Image acquisition parameters 80 kVp, 100 mAs
Coverage and slice thickness Maximal coverage possible based on CT
scanner configuration
(minimal coverage of 20 mm slab per
contrast bolus injection preferable;
two boluses is suggested to double
coverage for all CT scanners with under
4 cm detector length unless precluded
by contrast dose considerations)
focus on supratentorial
compartment/anterior circulation
5- to 10-mm-thick slices
field of view 24 cm
Slice orientation Parallel to hard palate
lowest slice through the proximal
middle/anterior cerebral artery
(above the orbits)
Contrast material 350 to 370 mg/mL iodinated contrast
material
high concentration, low/iso osmolar
contrast preferred
follow local guidelines for
contrast-induced nephropathy prevention
Contrast volume 35 to 50 mL, followed by 20 to 40 mL
saline flush
Injection rate 4 to 6 mL per second (power injector
required)
same injection rate for contrast and
saline
IV access 18 to 20 gauge IV line
right antecubital vein preferred
(for anatomical reasons, reduces pooling
of contrast, lowers the risk of
extravasation and minimizes streak
artifact at thoracic inlet in CTA portion)
Miscellaneous PCT can be performed before or
after CTA
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lected perfusion imaging parameters are based on first pass
tracer kinetic models and intended to provide the optimal
balance between requirements for maximization of image
quality and image analysis along with the need to minimize
contrast material dose and CT radiation dose. Although these
protocols are already applied at the time points listed above at
some institutions, their safety in terms of the total amount of
contrast injected, the renal function, and the total radiation
dose associated with the CT approach, requires further
investigation.
Acute Stroke Imaging Central Repository
The development of standardized, integrated, clinically useful
imaging paradigms in acute stroke will require consolidation
of existing data, prospective collection of new data, and the
development of tools to analyze data in a standardized
fashion at the time of image acquisition. This process will
also require the systematic accumulation of evidence that
specific imaging markers at determined time points accu-
rately predict radiographic and clinical outcomes. An Acute
Stroke Imaging Consortium could provide the framework for
linking international resources. This organization will require
leadership on the part of a small group of respected neuro-
imagers with a track record in collaborative endeavors.
Criteria for inclusion in the consortium and definition of the
structure for committees and representation will need to be
established. A charge to the leadership of such a consortium
will be to secure funding from public and private sources and
to foster collaboration with imaging equipment manufactur-
ers and stroke pharmaceutical/device companies.
An important initial step in effecting standardized anal-
ysis will be the creation of a central repository. This
approach has been adopted by other organizations, as evi-
denced in acute stroke initiatives such as the American Heart
Association’s Stroke - Get With the Guidelines program,1 the
Centers for Disease Control and Prevention’s (CDC) Paul
Coverdell National Acute Stroke Registry,2 and the NINDS
Specialized Program in Translational Research in Acute
Stroke (SPOTRIAS).3 The Alzheimer Disease Neuroimaging
Initiative (ADNI) group has successfully created an archive
of imaging datasets publicly available for research images,4
and there have also been nascent efforts to establish image
repositories by SPOTRIAS,3 the NIH Biomedical Informatics
Research Network (BIRN),5 the National Cancer Institute’s
cancer Biomedical Informatics Grid (caBIG),6 and the Inter-
national Consortium for Brain Mapping.7 Investigators in
Canada (Canadian Stroke Network and Canadian Stroke
Consortium), Germany (Stroke Competence Network),
United Kingdom and Scotland (NeuroGrid and SINAPSE),8,9
France (VIRAGE), Japan (Acute Stroke Imaging Standard-
ization Group - ASIST),10 Taiwan, and the international
investigators from the MR Stroke Collaborative Group11 and
the I KNOW12 and VISTA13 projects have also established
imaging repositories or are in the process of doing so. A
coordinated centralized resource building on these individual
efforts would significantly benefit the field of acute stroke
imaging.
The central repository should include a statistically mean-
ingful number of imaging studies obtained in acute stroke
patients admitted within 12 hours of symptom onset. In
addition to these imaging studies, relevant metadata such as
clinical information should be collected using standardized
definitions, including (1) scores of clinical stroke severity, eg,
NIH Stroke Scale, and other abstracted clinical parameters,
(2) treatment records, (3) subsequent imaging studies, as well
as information on (4) timing of symptom onset, admission,
imaging studies, interventions, and clinical evaluations, and
(5) the results of these evaluations indicative of functional
outcome, eg, modified Rankin scores, Barthel Index scores,
and cognitive scales. In addition, whenever possible, blood
should be banked from a subset of patients for the assessment
of biomarkers.
The concepts underlying image-guided selection of stroke
patients for therapy are that (1) only patients with reversible
ischemia are going to benefit from treatment, and (2) imaging
can identify these patients. To validate these concepts, it will
be important for the set of patients included in the central
repository either (1) no treatment decision is based on
imaging or (2) that matched control patients be identified in
the case of image-guided treatment decisions, and that (3) all
required imaging time points are obtained from all patients,
including those deemed ineligible for treatment.
Documentation of early reperfusion (whether spontaneous
or following therapy) is important because it strongly influ-
ences the appropriate predictive analysis and maximizes
ability to test acute imaging paradigms. Patients who achieve
early reperfusion are informative with regard to distinguish-
ing penumbra from core; nonrecanalizing patients are infor-
mative with regard to distinguishing imaging benign oligemia
from penumbra. Data would ideally be prospectively col-
lected, but some retrospective data collected as part of
existing networks and ongoing or completed trials, such as
SPOTRIAS,3 Echoplanar Imaging Thrombolysis Evaluation
Trial (EPITHET),11 MR RESCUE,14 Diffusion-weighted
imaging Evaluation For Understanding Stroke Evolution
(DEFUSE),15 etc, would also be included in the imaging
database, as long as the datasets satisfy the minimal require-
ments listed below in terms of imaging acquisition protocols
and time points for imaging studies. Contributors to the
repository will need to confirm consent of their patients and
approval from their institutional review board to allow
inclusion and utilization of anonymized data. The collected
information (including the source or raw imaging data) will
be deidentified. Also, the potential for unblinding during the
analysis of the scans collected in the imaging repository will
be considered.
The data collected in the repository will be made accessible
to qualified researchers worldwide, based on the recommen-
dations of a scientific committee that will evaluate proposed
research projects. The confidentiality of patients’ information
will be rigorously protected. Contributors will be offered
suitable reassurance over the uses to which their data may be
put, the acknowledgement that they as individuals and their
institutions will be granted for ensuing projects and develop-
ments, and an opportunity both to assist with the academic
leadership of the consortium and to access the repository for
projects of their own.
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Adequate funding will be required to implement a data
quality control program and to coordinate successful commu-
nication among participating sites. The cost of local study
coordination, data collection, and image transfer will need to
be compensated. The consortium will require financial re-
sources to reimburse centers for performance of additional
images or tests that are not otherwise clinically indicated,
facilitate communication with sites and data transfer, orga-
nize regular investigator meetings, support centralized anal-
ysis, recruit services of dedicated stroke neuroimaging bio-
statisticians and technology assessment experts, and develop
the technical infrastructure for the repository. Several mech-
anisms are available for potential funding through the NIH
(U01), the Foundation for NIH, and the Institute of Medicine.
Diverse partnerships will be explored with the NIH, private
foundations, and industry.
Pilot Projects
As pilot studies for the proposed Acute Stroke Imaging
Consortium, 3 “proof of concept” validation projects are
proposed that would build on the optimized test dataset
collected in the central repository.
Perfusion Imaging Processing
The first study would compare the different algorithms used
to process PCT and PWI datasets. Many researchers believe
that delay-insensitive or delay-compensated deconvolution
methods that take recirculation into account, with automatic
selection of 1 global or several local arterial input functions
(AIF) and of a venous output function (to correct for partial
volume averaging in the AIF), are the most appropriate
approach to process these datasets. However, a formal com-
parison with other analysis techniques (eg, nondeconvolution
based or maximal slope methods) is required to demonstrate
the superiority of this approach for predicting tissue fate and
clinical outcome. This systematic comparison will also deter-
mine which parameters have, or do not have, a significant
impact in terms of accurately representing acute perfusion
status and predicting subsequent tissue outcome. Parameters
studied will include cerebral blood flow, cerebral blood
volume, and mean transit time, among others. The optimal
method(s) should be most immune against slight raw image
quality differences resulting from the use of different scanner
hardware (ie, detector size configuration for multidetector CT
scanners, magnetic field strengths, RF coils, scan parameters,
injection protocols, and contrast agents used).
Imaging Prediction of Tissue Outcome
Still undetermined are the perfusion imaging parameters that
indicate that tissue is at risk for infarction or that adequate
reperfusion has taken place to prevent infarction. The “four
scan” approach described above (baseline, 1 to 6 hours, 24 to
72 hours and final tissue outcome) will be used to develop,
optimize, and validate imaging biomarkers of the infarct core
and the ischemic penumbra. It will establish the value of
baseline perfusion imaging in predicting final infarct size,
using tissue fate as the outcome variable. Analysis will adjust
for recanalization and reperfusion status, considered as a key
determinant of tissue outcome and one that can be influenced
by treatment. Different models of “operational” penumbra
will be compared, and the optimal parameters (eg, cerebral
blood flow, transit time, flow heterogeneity maps, etc) and
optimal thresholds (eg, quantitative versus relative, gray
matter versus white matter) to characterize the ischemic
penumbra will be determined. Emphasis will be placed on
quantitative approaches. A consensus on the appropriate
timing for deciding on the final infarct volume will be
developed. Similarly, standard definitions for recanalization
(ie, changes in the degree of arterial patency) and reperfusion
(ie, changes in the amount and spatial extent of perfusion
changes) will be established before the final analysis. This
analysis will incorporate patient characteristics at the time of
scan acquisition, such as heart rate, blood pressure, glucose
level, and hematocrit, which may have a significant impact on
the distribution of contrast within collateral fields, and
NIHSS which may reflect penumbral tissue shifting in and
out of electric dysfunction. Imaging data in patients who have
undergone reperfusion therapy and in those who have not will
be analyzed separately to determine whether the results are
the same for both groups.
Imaging Prediction of Clinical Outcome
One of the greatest challenges raised by pilot projects #1 and
#2 is on the lack of consensus with respect to the optimal
timing of outcome scans. Identification of key imaging
biomarkers would facilitate the prediction of clinical out-
come, define responders/nonresponders to therapy, and per-
mit monitoring of the efficacy of stroke treatment. This would
represent a significant advance in the field of stroke imaging.
The third study will determine the optimal timing to
perform imaging (48 hours, 1 week, 2 weeks, 1 month, 2
months, 3 months) to predict clinical outcomes at varying
time points in the course of stroke recovery (eg, 30 days, 3
months, 6 months, 12 months). Analysis will be stratified
according to management (eg, conservative care, IV/IA
thrombolysis, mechanical thrombectomy, collateral augmen-
tation, or neuroprotective agents). The optimal imaging mo-
dality (MRI versus CT) should be identified (many research-
ers believe that T2-FLAIR is the current best imaging
modality for the identification of final infarct, but this
requires validation). Clinical outcomes will be documented
using measures of global disability (eg, the Modified Rankin
Scale [mRS]), instrumental activities of daily living (eg,
Barthel Index [BI]), neurological deficit (eg, NIHSS), cogni-
tive function (neuropsychological testing), and quality of life.
All clinical outcome assessments should be undertaken in a
standardized manner and blinded to imaging and vice versa.
Inclusion of generic and stroke-specific quality of life scores,
and measures that identify values important to the patient
(patient-derived recovery targets), are considered critical.
This plan is in harmony with the Patient-Reported Outcomes
Measurement Information System (PROMIS), an NIH Road-
map initiative.16 Cost-effectiveness analyses should be inte-
grated into this and all future projects.
For this third pilot project, follow-up imaging studies will
be obtained at multiple time points. All datasets should be
contributed to the central repository.
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Deliverables
The goals of these 3 pilot projects, based on the clinical and
imaging data from the central repository, will be to provide
investigators with:
1. A standard set of imaging sequences to be performed at
specific time points.
2. A standardized image processing toolbox to analyze
these imaging sequences and to extract quickly (ideally
subminute but certainly 5 minutes) necessary infor-
mation on the selection of acute stroke patients for
acute therapies. This toolbox will include image regis-
tration and perfusion imaging software that will have
the capacity to process both CT and MRI datasets in a
reliable, reproducible, completely automated manner,
and will have the ability to seamlessly process DICOM
compatible data from any vendor’s scanner. The de-
veloped software will be able to reliably identify
patients who will benefit from a specific therapy—
many researchers believe that this will involve segmen-
tation of the infarct core and ischemic penumbra—and
hence assist in treatment decisions in a relevant time
window. Software performance will be expected not to
deteriorate in the real world environments where the
tool will be used. This toolbox will be developed in
collaboration with imaging manufacturers, so that it
can be integrated into their respective platforms, and
will ultimately be made publicly or commercially
available. This open source repository will facilitate
software upgrades over time, as new postprocessing
and analysis approaches develop. The data collected
in the central repository will serve as a standard
dataset to be used in benchmarking and validating
these upgrades.
Overall, these deliverables will be accommodated in the
clinical workflow of institutions using them and represent
minimal impediment to enrollment of acute stroke patients in
treatment protocols.
Next Steps
The deliverables outlined above, and the datasets stored in the
central repository, will be available for further analyses. The
initial focus will be on identifying the parameters that
optimize the selection of acute stroke patients who benefit
from reperfusion therapy. Other parameters of interest in-
clude aspects that will improve our understanding of collat-
eral perfusion, including determinants of tissue fate and
clinical outcome, and predictors of hemorrhagic transforma-
tion. A consensus on the definition of clinically meaningful
hemorrhagic transformation will need to be developed.
At this stage, the efforts of the Acute Stroke Imaging
Consortium will set the stage for 1 or more clinical trials.
Indeed, the institutions contributing to the central repository
will constitute a broad network of stroke care centers that
could form the basis for an acute stroke trial/imaging net-
work. They will all apply standardized imaging acquisition
protocols, and use the same toolbox to process images and
apply the same optimized criteria to interpret these processed
images. This process will significantly minimize any source
of variation other than the specific intervention (ie, drug or
device) that will be tested in the clinical trial. The perfor-
mance of the toolbox will be fully documented, facilitating
sample size calculations for such trials. Initially, the identi-
fied imaging biomarkers will need to be validated in clinical
trials with conventional clinical primary end points. Subse-
quently, it is anticipated that sample sizes will be reduced by
the increased power afforded by the use of imaging biomar-
kers. In addition, if validated, the shorter follow-up periods
that will be tested as part of the pilot projects will reduce loss
to follow-up and minimize variation in clinical outcome due
to unrelated events. This will greatly increase the feasibility
and decrease the duration and cost of stroke treatment clinical
trials.
Among the future stroke treatment clinical trials consid-
ered, particular interest has focused on 2 that have the
potential to increase the proportion of acute stroke patients
that are treated. The first trial is 1 of image-guided recanali-
zation therapy in an extended time window (3 to 6 or 9
hours); the second one would assess image-guided recanali-
zation therapy in wake-up stroke patients. Preliminary anal-
ysis (S.C. Johnston, personal communication, 2007) indicates
that increasing the time window for acute reperfusion therapy
from 3 hours to 6 hours could result in a 10-year societal
benefit of $US 60 million. Neuroprotective agents and
collateral enhancement could also be tested by the consor-
tium, and future analyses should include attention to tissue
repair, neurogenesis from stem cells, neurovascular remodel-
ing, and stroke recovery.
Conclusion
Validation and widespread use of imaging for acute stroke
patients’ management will be facilitated by the establishment
of an Acute Stroke Imaging Consortium, consisting of an
international, multi-institutional stroke neuroimaging net-
work. This consortium would provide an expertise structure
in which methodological issues in stroke imaging can be
addressed and consensus reached among different groups of
researchers and care providers. Initially, the consortium
would create a central repository of imaging studies and
clinical data obtained from acute stroke patients and develop
a standardized image analysis toolbox. These could subse-
quently benefit clinical trials of acute stroke treatments,
including, but not limited to, treatment of stroke patients in an
extended time window, treatment of patients with wake-up
stroke or those with long intervals between the time last seen
well and time of symptom discovery, and neuroprotective,
collateral enhancement, and neuroplasticity-stimulating ther-
apies. Ultimately, these efforts, combined with strategies to
change patient/population behavior to promote earliest pos-
sible admission to hospital, should result in more acute stroke
patients being appropriately treated and in an overall im-
provement of their outcome, as well as in reduced societal
costs from economic disability. Collaboration between aca-
demia, the NIH, the FDA, and industry is integral to the
successful realization of these aims.
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